Was haben wir aus der deutschen COPD-Kohorte COSYCONET gelernt und wie geht es weiter?

Zusammenfassung COSYCONET 1 ist die derzeit einzige international konkurrenzfähige deutsche COPD-Kohorte. Die Rekrutierung begann Ende 2010 und endete im Dezember 2013. Sie resultierte in 2741 Patienten mit der Diagnose einer COPD, die in der Folge in regelmäßigen Visiten nachuntersucht wurden. Diese Visiten umfassten eine umfangreiche funktionelle und klinische Charakterisierung. Auf der Basis dieses hochwertigen Datensatzes war es möglich, eine Vielzahl klinischer Fragen zu beantworten. Diese reichten vom Verschreibungsverhalten über die genaue Analyse verschiedener Komorbiditäten, v.a. kardiovaskulärer Art, bis zu Biomarkern, radiologischen und gesundheitsökonomischen Analysen. Inzwischen wurden mehr als 60 Publikationen zu COSYCONET international veröffentlicht. Die nachstehende Arbeit liefert eine Übersicht über alle bislang erhaltenen Ergebnisse, mit einem besonderen Fokus darauf, deren wechselseitigen Zusammenhang sowie die möglichen praktischen Konsequenzen herauszuarbeiten. Ferner werden einige Informationen über die Folgestudie COSYCONET 2 gegeben.

[1]  H. Watz,et al.  Association of coronary artery calcification with clinical and physiological characteristics in patients with COPD: Results from COSYCONET. , 2022, Respiratory medicine.

[2]  R. Holle,et al.  Basic Determinants of Disease Knowledge in COPD Patients: Results from COSYCONET , 2022, Patient preference and adherence.

[3]  Claus F. Vogelmeier,et al.  Differences in the Measurement of Functional Residual Capacity Between Body Plethysmographs of Two Manufacturers , 2022, International journal of chronic obstructive pulmonary disease.

[4]  C. Kropf-Sanchen,et al.  Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease: results from COSYCONET , 2022, Scientific reports.

[5]  C. Kropf-Sanchen,et al.  Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment , 2022, Scientific reports.

[6]  H. Watz,et al.  IgE is associated with exacerbations and lung function decline in COPD , 2022, Respiratory Research.

[7]  H. Watz,et al.  Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET , 2021, International journal of chronic obstructive pulmonary disease.

[8]  Bertram J Jobst,et al.  Quantification of pulmonary perfusion abnormalities using DCE-MRI in COPD: comparison with quantitative CT and pulmonary function , 2021, European Radiology.

[9]  F. Herth,et al.  Oxygenated Hemoglobin Predicts Outcome in Patients with Chronic Lung Allograft Dysfunction , 2021, Respiration.

[10]  Bertram J Jobst,et al.  Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET , 2021, Respiratory Research.

[11]  H. Kauczor,et al.  Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities , 2021, Clinical Research in Cardiology.

[12]  P. Boor,et al.  Measurement of urinary Dickkopf-3 uncovered silent progressive kidney injury in patients with chronic obstructive pulmonary disease. , 2021, Kidney international.

[13]  H. Kauczor,et al.  Impact of the COVID-19 pandemic on the behaviour and health status of patients with COPD: results from the German COPD cohort COSYCONET , 2021, ERJ Open Research.

[14]  H. Watz,et al.  COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort. , 2021, Respiratory medicine.

[15]  H. Kauczor,et al.  Echo Time‐Dependent Observed Lung T1 in Patients With Chronic Obstructive Pulmonary Disease in Correlation With Quantitative Imaging and Clinical Indices , 2021, Journal of magnetic resonance imaging : JMRI.

[16]  R. Holle,et al.  Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences , 2021, International journal of chronic obstructive pulmonary disease.

[17]  H. Watz,et al.  Prognostic Value of Oxygenated Hemoglobin Assessed during Acute Exacerbations of Chronic Pulmonary Disease , 2021, Respiration.

[18]  R. Holle,et al.  Deterioration and Mortality Risk of COPD Patients Not Fitting into Standard GOLD Categories: Results of the COSYCONET Cohort , 2021, Respiration.

[19]  R. Holle,et al.  Impact of Education on COPD Severity and All-Cause Mortality in Lifetime Never-Smokers and Longtime Ex-Smokers: Results of the COSYCONET Cohort , 2020, International journal of chronic obstructive pulmonary disease.

[20]  R. Holle,et al.  Utilization and determinants of use of non-pharmacological interventions in COPD: Results of the COSYCONET cohort. , 2020, Respiratory medicine.

[21]  H. Kauczor,et al.  Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET. , 2020, Respiratory medicine.

[22]  H. Watz,et al.  Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET , 2020, ERJ Open Research.

[23]  H. Kauczor,et al.  Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET , 2020, Scientific Reports.

[24]  P. Dorinsky,et al.  Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.

[25]  R. Holle,et al.  Health-related quality of life associates with change in FEV1 in COPD: results from the COSYCONET cohort , 2020, BMC Pulmonary Medicine.

[26]  C. Vogelmeier,et al.  The impact of COPD on polyneuropathy: results from the German COPD cohort COSYCONET , 2020, Pneumologie.

[27]  S. Blankenberg,et al.  High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study , 2019, European Respiratory Journal.

[28]  T. Brinker,et al.  Time-updated resting heart rate predicts mortality in patients with COPD , 2019, Clinical Research in Cardiology.

[29]  C. Kropf-Sanchen,et al.  The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort , 2019, Respiratory Research.

[30]  H. Kauczor,et al.  CAT score single item analysis in patients with COPD: results from COSYCONET , 2019, Pneumologie.

[31]  H. Watz,et al.  Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort , 2019, Patient preference and adherence.

[32]  Hans-Peter Lenhof,et al.  Low miR-150-5p and miR-320b Expression Predicts Reduced Survival of COPD Patients , 2019, Cells.

[33]  H. Watz,et al.  Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort , 2019, International journal of chronic obstructive pulmonary disease.

[34]  H. Watz,et al.  Consequences of chronic kidney disease in chronic obstructive pulmonary disease , 2019, Respiratory Research.

[35]  R. Holle,et al.  Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET , 2019, International journal of chronic obstructive pulmonary disease.

[36]  H. Kauczor,et al.  Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort. , 2019, Respiratory medicine.

[37]  H. Watz,et al.  Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD , 2019, Respiratory Research.

[38]  H. Watz,et al.  Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study , 2019, Respiratory Research.

[39]  Bertram J Jobst,et al.  Comparison of quantitative regional perfusion‐weighted phase resolved functional lung (PREFUL) MRI with dynamic gadolinium‐enhanced regional pulmonary perfusion MRI in COPD patients , 2018, Journal of magnetic resonance imaging : JMRI.

[40]  C. Vogelmeier,et al.  Medical Treatment of COPD. , 2018, Deutsches Arzteblatt international.

[41]  H. Watz,et al.  Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort , 2018, International journal of chronic obstructive pulmonary disease.

[42]  K. Rabe,et al.  Influence of body mass on predicted values of static hyperinflation in COPD , 2018, International journal of chronic obstructive pulmonary disease.

[43]  H. Kauczor,et al.  Design and application of an MR reference phantom for multicentre lung imaging trials , 2018, PloS one.

[44]  H. Watz,et al.  Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach , 2018, Respiratory Research.

[45]  Christina Backes,et al.  Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development , 2018, Genom. Proteom. Bioinform..

[46]  H. Watz,et al.  Left ventricular volume and wall stress are linked to lung function impairment in COPD. , 2017, International journal of cardiology.

[47]  P. Grenier,et al.  Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans , 2018, Chronic respiratory disease.

[48]  J. Hohlfeld,et al.  Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. , 2018, The Lancet. Respiratory medicine.

[49]  H. Watz,et al.  Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. , 2018, Respiratory medicine.

[50]  R. Holle,et al.  Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD. , 2018, Pulmonary pharmacology & therapeutics.

[51]  J. Vestbo,et al.  The revised GOLD 2017 COPD categorization in relation to comorbidities , 2018, Pneumologie.

[52]  R. Holle,et al.  The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort , 2017, International journal of chronic obstructive pulmonary disease.

[53]  Sally J. Singh,et al.  Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease. , 2017, Journal of the American Medical Directors Association.

[54]  H. Kauczor,et al.  Cardiovascular risk in patients with alpha-1-antitrypsin deficiency , 2017, Respiratory Research.

[55]  R. Holle,et al.  Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort , 2017, PloS one.

[56]  R. Holle,et al.  Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients , 2017, Respiratory Research.

[57]  R. Holle,et al.  Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences‐Comorbidities Network Study , 2017, American journal of respiratory and critical care medicine.

[58]  R. Holle,et al.  Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort , 2017, Respiratory Research.

[59]  R. Holle,et al.  Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies – A Novel Stepwise Approach by Evaluation of Medication , 2016, PloS one.

[60]  R. Holle,et al.  Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies , 2016, Respiratory Research.

[61]  R. Holle,et al.  Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities , 2016, BMC Pulmonary Medicine.

[62]  R. Holle,et al.  The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. , 2016, Respiratory medicine.

[63]  S. Petersen,et al.  Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. , 2016, American journal of respiratory and critical care medicine.

[64]  R. Holle,et al.  Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. , 2016, Respiratory medicine.

[65]  Joyce D. Schroeder,et al.  Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus , 2014, BMC Pulmonary Medicine.

[66]  B. Celli,et al.  Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[67]  W. Rief,et al.  Mental disorders and quality of life in COPD patients and their spouses , 2008, International journal of chronic obstructive pulmonary disease.

[68]  I. Kopp,et al.  Die Nationale VersorgungsLeitlinie COPD , 2007, Medizinische Klinik.

[69]  C. Vogelmeier,et al.  [Systemic manifestations and comorbidities in patients with chronic obstructive pulmonary disease (COPD) and their effect on clinical state and course of the disease--an overview of the cohort study COSYCONET]. , 2010, Deutsche medizinische Wochenschrift.

[70]  G. Ollenschläger,et al.  [The German Program for Disease Management Guidelines: COPD Guideline 2006. Short review]. , 2006, Medizinische Klinik.